Search results for "acids"

showing 10 items of 3520 documents

ETC-1002: A future option for lipid disorders?

2014

ETC-1002 is a new investigational low density lipoprotein cholesterol (LDL-C)-lowering agent (Esperion Therapeutics, Inc.). ETC-1002 is a dicarboxylic acid derivative with a novel mechanism of action targeting two hepatic enzymes - adenosine triphosphate-citrate lyase (ACL) and adenosine monophosphate-activated protein kinase (AMPK), inhibiting sterol and fatty acid synthesis and promoting mitochondrial long-chain fatty acid oxidation. This agent is currently in phase II clinical research. Available data report that ETC-1002 significantly decreased LDL-C levels (up to 32%) in both patients with normal and elevated baseline levels of triglycerides. Such beneficial effect is superior to curre…

Apolipoprotein BLow density lipoprotein cholesterolBlood PressureAMP-Activated Protein Kinaseschemistry.chemical_compoundMiceMulticenter Studies as TopicDicarboxylic AcidsBeta oxidationHypolipidemic AgentsRandomized Controlled Trials as TopicHypolipidemic AgentbiologyFatty AcidsHyperlipidemiaTolerabilityLiverlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAMP-Activated Protein Kinasemedicine.drugHumanmedicine.medical_specialtyStatinmedicine.drug_classHypercholesterolemiaHyperlipidemiasClinical Trials Phase II as TopicInternal medicinemedicineAnimalsHumansFatty acid synthesisApolipoproteins BAnimalBody WeightDicarboxylic AcidAMPKCholesterol LDLAdenosineSterolCardiometabolic riskRatsETC-1002Disease Models AnimalEndocrinologychemistrybiology.proteinATP Citrate (pro-S)-LyaseRatFatty AcidLipid lowering therapy
researchProduct

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

2020

Background Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its average effect on plasma lipids in humans and its safety profile. Methods and findings We carried out a systematic review and meta-analysis of phase II and III randomized controlled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Scopus, Google Scholar, and Web of Science databases were searched, with no language restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids and high-…

Apolipoprotein BPublication Ethics030204 cardiovascular system & hematologyCardiovascularGastroenterologyLipoprotein particleMedical and Health SciencesBiochemistrychemistry.chemical_compoundDatabase and Informatics Methods0302 clinical medicineMathematical and Statistical TechniquesAnticholesteremic Agents Apolipoproteins B Cholesterol Cholesterol LDL Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Dicarboxylic Acids Fatty Acids Humans Hypercholesterolemia Peptide Fragments Randomized Controlled Trials as TopicLipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert PanelMedicine and Health SciencesDicarboxylic Acids030212 general & internal medicineDatabase SearchingResearch IntegrityRandomized Controlled Trials as Topicmedicine.diagnostic_testbiologyAnticholesteremic AgentsStatisticsFatty AcidsRDrugsGeneral MedicineMetaanalysisSerious Mental IllnessLipidsPhase III as TopicMental HealthCholesterolPhysical SciencesMedicineResearch Articlemedicine.medical_specialtyRMScience PolicyLipoproteinsHypercholesterolemiaBempedoic acid hypercholesterolemia lipid profile hsCRPResearch and Analysis MethodsLDL03 medical and health sciencesClinical Trials Phase II as TopicInternal medicineGeneral & Internal MedicinemedicineHumansClinical TrialsStatistical MethodsApolipoproteins BPharmacologyPlasma Proteinsbusiness.industryCholesterolPhase II as TopicStatinsBiology and Life SciencesProteinsOdds ratioCholesterol LDLConfidence intervalPeptide FragmentschemistryClinical Trials Phase III as Topicbiology.proteinUric acidCreatine kinaseLipid profilebusinessDigestive DiseasesMathematicsPLoS Medicine
researchProduct

Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives

2020

Several lines of evidence now attest that lipoprotein[a] (Lp[a]) is a significant risk factor for many cardiovascular disorders. This enigmatic lipoprotein, composed of a single copy of apolipoprotein B (apoB) and apolipoprotein[a] (apo [a]), expresses peculiar metabolism, virtually independent from lifestyle interventions. Several therapeutic options have hence been proposed for lowering elevated Lp[a] values, with or without concomitant effect on low density lipoprotein (LDL) particles, mostly encompassing statins, ezetimibe, nicotinic acid, lipoprotein apheresis, and anti-PCSK9 monoclonal antibodies. Since all these medical treatments have some technical and clinical drawbacks, a novel s…

Apolipoprotein Bmedicine.drug_classgovernment.form_of_governmentAntisense therapyHyperlipidemias030204 cardiovascular system & hematologyPharmacologyAntisense therapy; Apolipoprotein[a]; Cardiovascular disease; Lipoprotein[a]Monoclonal antibody03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeLipoprotein[a]Internal MedicinemedicineHumans030212 general & internal medicineAntisense therapybiologybusiness.industryLipoprotein(a)Cardiovascular diseaseLipoproteins LDLchemistryConcomitantLow-density lipoproteinBlood Component Removalbiology.proteingovernmentlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessApolipoprotein[a]Lipoprotein(a)Lipoproteinmedicine.drugEuropean Journal of Internal Medicine
researchProduct

The effect of the APOE polymorphism on HDL-C concentrations depends on the cholesterol ester transfer protein gene variation in a Southern European p…

2005

Abstract Background Apolipoprotein E (ApoE) locus has consistently shown a significant association with low-density lipoprotein cholesterol (LDL-C). However, its impact on high-density lipoprotein cholesterol (HDL-C) has been highly controversial suggesting that it may be context-dependent. We examined the gene–gene interaction between the common ApoE and the CETP polymorphisms in determining HDL-C concentrations in men and women from the general population. Methods 550 unrelated Caucasian subjects were randomly selected from a Mediterranean Region in Spain. Plasma lipids, anthropometric, clinical and lifestyle variables were measured. Common ApoE and CETP-TaqIB polymorphisms were determine…

Apolipoprotein EAdultMalemedicine.medical_specialtyAdolescentGenotypeClinical BiochemistryPopulationPhysical exerciseLocus (genetics)BiologyBiochemistryWhite PeopleApolipoproteins EGene FrequencyInternal medicineGenotypeCholesterylester transfer proteinmedicineHumansAlleleeducationAllelesAgedGlycoproteinsGeneticsAged 80 and overeducation.field_of_studyPolymorphism GeneticModels GeneticBiochemistry (medical)Cholesterol HDLGenetic VariationGeneral MedicineMiddle AgedLipidsCholesterol Ester Transfer ProteinsEndocrinologySpainbiology.proteinlipids (amino acids peptides and proteins)FemaleCarrier ProteinsBody mass indexClinica chimica acta; international journal of clinical chemistry
researchProduct

Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease.

2005

Triglycerides (TGs) are vehicled by multiple particles with different abilities to promote atherosclerosis. Among plasma TG-rich lipoproteins (TRLs), subspecies may or may not contain apolipoprotein E (apoE) molecules: in this study, we evaluated the relative contribution of apoE-rich and apoE-poor TRLs to coronary atherosclerosis. We selected a group of males with premature coronary artery disease (CAD) without any of the classical nonlipid risk factors and/or high plasma lipid levels and evaluated the plasma concentration of TRL subspecies in comparison with healthy controls. Patients with CAD and controls had total cholesterol and TG levels within the normal range (despite slightly, even…

Apolipoprotein EAdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismCoronary Artery DiseaseChromatography AffinityApolipoproteins ECoronary artery diseasechemistry.chemical_compoundEndocrinologyApolipoproteins EInternal medicinemedicineHumansInsulinCoronary atherosclerosisTriglyceridesbiologyTriglycerideCholesterolCholesterol HDLLipoprotein(a)Cholesterol LDLMiddle Agedmedicine.diseaseEndocrinologyapoE triglyceride-rich lipoproteins coronary artery diseaseLogistic ModelschemistryMultivariate Analysisbiology.proteinlipids (amino acids peptides and proteins)Electrophoresis Polyacrylamide GelLipoproteinLipoprotein(a)Metabolism: clinical and experimental
researchProduct

Association of plasma markers of cholesterol homeostasis with metabolic syndrome components. A cross-sectional study.

2011

Abstract Background and aims Increased plasma phytosterols, which reflect enhanced cholesterol absorption, have been related to an increased risk of cardiovascular disease (CVD). However, high CVD risk conditions, such as obesity, diabetes and the metabolic syndrome (MetS) have been associated with reduced cholesterol absorption. We investigated associations between plasma noncholesterol sterols and MetS components. Methods and results With a cross-sectional design, we related MetS components to plasma noncholesterol sterol-to-cholesterol ratios measured by gas chromatography in 674 dyslipidemic patients and 361 healthy subjects participating in a prospective cohort study. Plasma phytostero…

Apolipoprotein EAdultMalemedicine.medical_specialtyGenotypeEndocrinology Diabetes and MetabolismMedicine (miscellaneous)LathosterolBiologychemistry.chemical_compoundHigh-density lipoproteinApolipoproteins ERisk FactorsInternal medicineDiabetes mellitusmedicineHomeostasisHumansProspective StudiesProspective cohort studyMetabolic SyndromeNutrition and DieteticsPhytosterolsOdds ratioMiddle Agedmedicine.diseaseLipid MetabolismSitosterolsEuropean Prospective Investigation into Cancer and NutritionEndocrinologyCholesterolCross-Sectional StudiesPhenotypechemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleMetabolic syndromeCardiology and Cardiovascular MedicineBiomarkersNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea.

2016

Obstructive sleep apnea (OSA) is associated with dyslipidemia and increased cardiovascular risk. We assessed the effects of apolipoprotein E ( APOE) genotype on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle size and lipid subclasses (separated by gradient gel electrophoresis) in patients with OSA. Stable patients (n = 181) prospectively recruited underwent full polysomnography. Both LDL particle size and LDL I proportion were reduced from ∊3∊3 homozygotes to ∊2 carriers and to ∊4 carriers (analysis of variance: P = .024; P = .040, respectively); carriers of the ∊4 allele of the APOE genotype had significantly lower LDL particle size and LDL I proportion compared…

Apolipoprotein EAdultMalemedicine.medical_specialtyGenotypePolysomnographyApolipoprotein E4Statistics as TopicPolysomnography030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInsulin resistanceApolipoproteins EInternal medicineGenotypemedicineHumansGenetic Predisposition to Disease030212 general & internal medicineProspective StudiesParticle SizeAgedSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industryGenetic Carrier ScreeningMiddle Agedmedicine.diseaseObstructive sleep apneaLipoproteins LDLEndocrinologyCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemiaLipoproteinAngiology
researchProduct

Low and very low density lipoprotein composition and resistance to copper-induced oxidation are not notably modified in smokers.

1997

To study whether tobacco use was associated with oxidative phenomena affecting lipoproteins, we estimated susceptibility of LDL and VLDL to an in vitro copper-mediated oxidation, and measured serum autoantibody titers against oxidized LDL in 45 middle-age healthy nonsmokers, 35 smokers and 37 ex-smokers of both sexes, taking into account the detailed lipid composition of the lipoproteins. VLDL from female smokers had higher triglyceride, phospholipid, apolipoprotein E and alpha-tocopherol content and showed a higher rate of copper-induced oxidation in comparison with those from nonsmokers (P < or = 0.05) whereas the relative composition of these particles in saturated, mono- or poly-unsatur…

Apolipoprotein EAdultMalemedicine.medical_specialtyVery low-density lipoproteinAdolescentmedicine.medical_treatmentClinical BiochemistryPhospholipidLipoproteins VLDLBiochemistrychemistry.chemical_compoundInternal medicinemedicineHumansVitamin ELipoprotein oxidationAgedAutoantibodieschemistry.chemical_classificationTriglycerideVitamin EBiochemistry (medical)SmokingProteinsGeneral MedicineMiddle AgedLipidsLipoproteins LDLEndocrinologychemistryBiochemistryLow-density lipoproteinlipids (amino acids peptides and proteins)FemaleOxidation-ReductionCopperPolyunsaturated fatty acidClinica chimica acta; international journal of clinical chemistry
researchProduct

Vascular effects of diet supplementation with plant sterols.

2008

Objectives The purpose of this study was to evaluate vascular effects of diet supplementation with plant sterol esters (PSE). Background Plant sterol esters are used as food supplements to reduce cholesterol levels. Their effects on endothelial function, stroke, or atherogenesis are not known. Methods In mice, plasma sterol concentrations were correlated with endothelial function, cerebral lesion size, and atherosclerosis. Plasma and tissue sterol concentrations were measured by gas-liquid chromatography-mass spectrometry in 82 consecutive patients with aortic stenosis. Results Compared with those fed with normal chow (NC), wild-type mice fed with NC supplemented with 2% PSE showed increase…

Apolipoprotein EAortic valveMalemedicine.medical_specialtyDiet therapyArteriosclerosisCardiovascular SystemBrain Ischemiachemistry.chemical_compoundMiceEzetimibeRisk FactorsInternal medicinepolycyclic compoundsmedicineAnimalsHumansEndotheliumAgedCholesterolbusiness.industryPhytosterolsSterolMice Inbred C57BLEndocrinologymedicine.anatomical_structurechemistryCirculatory systemDietary Supplementslipids (amino acids peptides and proteins)FemalePlant PreparationsCardiology and Cardiovascular MedicinebusinessBlood vesselmedicine.drugJournal of the American College of Cardiology
researchProduct

Liver is not the unique site of synthesis of beta 2-glycoprotein I (apolipoprotein H): evidence for an intestinal localization.

1997

Apolipoprotein H is a protein of about 50 kilodaltons, structurally related to the regulators of the complement activation family. Its physiological function is poorly understood but it has been implicated in lipid metabolism and coagulative pathways. The major site of synthesis is thought to be the liver. Several reports indicate that apolipoprotein H is the antigen of the antiphospholipid antibodies and also behaves as an acute-phase reactant. Moreover, 40% of plasma apolipoprotein H is associated with very low-density lipoprotein, high-density lipoprotein, and postprandial chylomicrons. In this study we investigated other sites of synthesis by reverse transcription/polymerase chain react…

Apolipoprotein EApolipoprotein BClinical BiochemistryGene ExpressionBiologyPolymerase Chain ReactionCell LineHumansRNA MessengerIntestinal MucosaDNA PrimersGlycoproteinsMessenger RNABase SequenceLipid metabolismMolecular biologyImmunohistochemistryApolipoproteinsBiochemistryLiverbeta 2-Glycoprotein Ibiology.proteinlipids (amino acids peptides and proteins)Apolipoprotein C2Apolipoprotein HLipoproteinChylomicronInternational journal of clinicallaboratory research
researchProduct